Mircofluidics launches continuous nanocrystallisation tech

By Staff Reporter

- Last updated on GMT

Related tags Chemical engineering

Microfluidics chose Interphex 2010 in New York, US to unveil a new processing technology that it claims can help manufacturers save time and money by switching from batch to continuous particle production.

The Microfluidics Reaction Technology (MRT) system combines active pharmaceutical ingredient (API) nanoparticle production with multiphase chemical reactions and nanoencappsulation in a single production unit.

This approach has a number of cost and timing advantages over traditional pharmaceutical nanoparticle production methods, according to Microfluidics’ chief technology officer Thomai Panagiotou.

Currently, the typical batch crystallization process involves several steps, often in locations across the country, which can take weeks. MRT simplifies the process and has been proven to reduce production time to a matter of hours​.”

Microfluidics also suggested that MRT’s consistency and stability enables the creation of particles of previously unattainable dimensions.

The firm went on to cite the production of azithromycin with a z-average particle size of 82 nm as an example of what the MRT platform has been able to achieve to date.

Simultaneous launch in Japan

Microfluidics also chose Interphex to announce the official launch of MRT in Japan in collaboration with distribution partner Powrex, which simultaneously unveiled the system at a symposium in Osaka.

Powrex president Takeshi Takashima suggested that the MRT platform would fit well with the Japanese pharmaceutical manufacturing sector’s approach to drug development and production.

Japanese companies and researchers are visionary innovators, and we are pleased to offer them the latest nanomaterials processing methods available to achieve new goals​.”

Microfluidics has also applied for a Japanese patent for the MRT platform, which is the first time it has sought such protection outside the US.

CEO Michael Ferrara explained that: “Because we have such confidence in our valued partner, POWREX, we are filing for a patent and are eager to introduce this revolutionary platform technology to Japan.”

He added that: “Powrex engineers have been well trained to understand how to make the most of the results through a combination of a unique processor and expert process development skills.

Related news

Show more

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...